• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Nanoparticles: An industry buzzword meets reality

May 31, 2017 By Sarah Faulkner

Team at Latona TherapeuticsYoung startups backed by nanoparticle tech face a world hurdles before reaching the clinic. It’s been decades since the first innovations with nanotechnology – and experts are asking, “Where are all the drugs?”

It’s been more than 20 years since the FDA approved the first nanoparticle drug, Doxil. At the time, nanoparticles were heralded as a way to more efficiently deliver drugs that traditionally come with burdensome side effects, such as chemotherapy.

Since then, scientists have published an array of preclinical studies and academic papers evaluating various types of nanoparticles, including liposomes, antibodies and more. But some experts point out that in many instances, nanoparticle technology stalls before it can even get to the clinic.

“Well, they haven’t really lived up to their promise,” said Keith Horspool, VP of pharmaceutics at Boehringer Ingelheim.

Get the full story at our sister site, Medical Design & Outsourcing.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Nanoparticles, Pharmaceuticals, Preclinical Trials Tagged With: Boehringer Ingelheim Pharmaceuticals, Catalent, Cerulean Pharma Inc., Dicerna Pharmaceuticals, latonatherapeutics

IN CASE YOU MISSED IT

  • Medtronic to invest $50M in India Diabetes center
  • Flat Medical partners with Mercury Medical on smart syringe distribution
  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS